Oncogenic Ki-ras Confers a More Aggressive Colon Cancer Phenotype through Modification of Transforming Growth Factor-beta Receptor III*

Zhongfa Yan, Xiaobing Deng, and Eileen FriedmanDagger

From the Department of Pathology, Upstate Medical University, State University of New York, Syracuse, New York 13210

Received for publication, May 25, 2000, and in revised form, August 31, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Transforming growth factor-beta 1 (TGF-beta 1) can act as a tumor suppressor or a tumor promoter depending on the characteristics of the malignant cell. Each of three Ki-rasG12V transfectants of HD6-4 colon cancer cells had been shown to be more aggressive in vivo than controls in earlier studies (Yan, Z., Chen, M., Perucho, M., and Friedman, E. (1997) J. Biol. Chem. 272, 30928-30936). We now show that stable expression of oncogenic Ki-rasG12V converts the HD6-4 colon cancer cell line from insensitive to TGF-beta 1 to growth-promoted by TGF-beta 1. Each of three Ki-rasG12V transfectants responded to TGF-beta 1 by an increase in proliferation and by decreasing the abundance of the Cdk inhibitor p21 and the tumor suppressor PTEN, whereas each of three wild-type Ki-ras transfectants remained unresponsive to TGF-beta 1. The wild-type Ki-ras transfectants lack functional TGF-beta receptors, whereas all three Ki-rasG12V transfectants expressed functional TGF-beta receptors that bound 125I-TGF-beta 1. The previous studies showed that in cells with wild-type Ki-ras, TGF-beta receptors were not mutated, and receptor proteins were transported to the cell surface, but post-translational modification of TGF-beta receptor III (Tbeta RIII) was incomplete. We now show that the betaglycan form of Tbeta RIII is highly modified following translation when transiently expressed in Ki-rasG12V cells, whereas no such post-translational modification of Tbeta RIII occurs in control cells. Antisense oligonucleotides directed to Ki-Ras decreased both Tbeta RIII post-translational modification in Ki-rasG12V cells and TGF-beta 1 down-regulation of p21, demonstrating the direct effect of mutant Ras. Therefore, one mechanism by which mutant Ki-Ras confers a more aggressive tumor phenotype is by enhancing Tbeta RIII post-translational modification.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The TGF-beta 1 family of proteins number >25 and regulate cell growth and differentiation as well as morphogenesis and angiogenesis (1, 2). There are three mammalian isoforms, TGF-beta 1, TGF-beta 2, and TGF-beta 3, which are structurally very similar with nine conserved cysteines. The TGF-beta s belong to a superfamily of structurally related proteins including the activins, inhibins, and bone morphogenic proteins (3). The TGF-beta s induce diverse biological responses by binding to the high affinity receptors Tbeta RI (53 kDa) and Tbeta RII (75 kDa), which function as a heterodimer. Both receptors have a cysteine-rich extracellular domain, one transmembrane segment, and a cytoplasmic tail that includes a serine/threonine kinase domain (4, 5). Constitutively phosphorylated Tbeta RII binds TGF-beta 1, which then recruits Tbeta RI into the complex. Tbeta RI is transphosphorylated by Tbeta RII and propagates the signal by its kinase activity to downstream substrates (6). Two other cell-surface TGF-beta -binding proteins are the type III receptors betaglycan and endoglin, which modulate cellular responses to TGF-beta , but have no signaling sequences. Betaglycan and endoglin may function by regulating TGF-beta access to Tbeta RII (7-9). Tbeta RIII receptors are not found in every TGF-beta -responsive cell and are down-regulated during myoblast differentiation into myotubes (10).

The chief mediators of TGF-beta signaling are the SMAD family of structurally related proteins. Receptor-activated SMAD proteins form heterotrimeric complexes and translocate to the nucleus, where they interact with other transcription factors to drive TGF-beta 1-induced transcription (11). Transcription factors interacting with SMAD proteins include FAST-1 and FAST-2 (12, 13) and the c-Jun/c-Fos heterodimer (14). The cooperation of SMAD proteins with other transcription factors suggests that TGF-beta 1 induces multiple parallel signaling pathways. Additional reported members of the TGF-beta signaling pathways include the SMAD-interacting protein SARA and related proteins (15), Ras (16-18), the Raf homolog TAK-1 (19), TAK-1-associated proteins TAB-1 and TAB-2 (20), and the FK506- and rapamycin-binding protein FKBP-12 and the alpha -subunit of farnesyltransferase (21-23).

Several investigators have reported that expression of oncogenic Ras confers resistance to the growth inhibitory properties of TGF-beta (24-27). In mouse mammary epithelial cells, oncogenic Ras was shown to constitutively activate the MAPKs ERK1 and ERK2. Activated ERK1/ERK2 phosphorylate multiple sites within the linker regions of SMAD2 and SMAD3, decreasing, but not totally eliminating, SMAD translocation into the nucleus following TGF-beta stimulation (28). Oncogenic Ras, by this mechanism, eliminates the antimitogenic activity of TGF-beta . However, treatment of the same oncogenic Ras-transformed cells with TGF-beta 1 causes an epithelial-to-fibroblastoid conversion to a more invasive phenotype (29), showing that these cells maintained some TGF-beta signaling pathways, which mediated tumor aggressiveness. In the mouse skin model of chemical carcinogenesis, one Ha-ras gene is activated by mutation and the normal is allele lost, causing the cells to undergo a morphological transformation to a highly invasive spindle phenotype that can be induced in synergy with TGF-beta 1 (30).

We now report another system in which oncogenic Ras and TGF-beta 1 work together to enhance tumorigenicity and also report initial studies on the mechanism of this response. Goblet cells compose ~20% of the colon epithelial cell population and are resistant to growth inhibition by TGF-beta 1 in vivo, becoming enriched relative to other colon epithelial cells in mice injected with recombinant TGF-beta 1 (31). Colon goblet cell lines are also resistant to the growth inhibitory effects of TGF-beta 1 (32, 33). We now show that oncogenic Ras up-regulates post-translational modification of the type III TGF-beta receptor in the HD6-4 colon goblet cell line. Unexpectedly, TGF-beta 1 induces cell proliferation in the presence of oncogenic Ki-ras and, in parallel, down-regulates the Cdk inhibitor p21Cip1/Waf1 and the tumor suppressor phosphatase PTEN.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- 125I-TGF-beta 1 and [3H[TdR were obtained from PerkinElmer Life Sciences. Human recombinant TGF-beta 1 was from R&D Systems. Protein A-Sepharose was obtained from Amersham Pharmacia Biotech. Polyvinylidene difluoride transfer paper (Immobilon-P) was from Millipore Corp. Antibody TED1 to PTEN was the kind gift of Dr. Hong Sun (Department of Genetics, Yale University School of Medicine). Antibodies to Tbeta RI/Alk5, TGF-beta 1, and Tbeta RII were purchased from Santa Cruz Biotechnology; antibodies to phospho-SMAD2 and total SMAD2 were from Upstate Biotechnology, Inc.; antibody to betaglycan/Tbeta RIII was from R&D Systems; and mouse monoclonal IgG2a clone 70 to p21Cip1 and anti-phosphotyrosine monoclonal antibody PY69 were purchased from Transduction Laboratories. Phosphorothiolated oligodeoxynucleotides were a gift of Dr. Brett Monia (Isis Pharmaceuticals, Carlsbad, CA). Isis-13177 is a 20-mer of random sequence, and Isis-6957 is a 20-mer targeted to the 5'-untranslated region of Ki-Ras (CAG-TGC-CTG-CGC-CGC-GCT-CG). This sequence is found within the promoter region of the c-Ki-ras2 gene cloned into pMiKVal12 (see below) ~60 bp upstream of the translational start site. Endoglycosidase F (N-glycosidase F-free), also known as endo-beta -N-acetylglucosidase F, was purchased from Roche Molecular Biochemicals. All other reagents, including chondroitinase ABC and heparitinase III, were from Sigma.

Antisense Oligonucleotide Treatment-- Treatment of Ki-ras transfectants was essentially as described (34). Cells were seeded at 2 × 105/well in six-well plates. 48 h later, the cells were washed with prewarmed serum-free insulin transferrin/selenious acid-supplemented DMEM and then incubated in this medium with a fixed ratio of oligonucleotide to Lipofectin (2.4 µl of Lipofectin/100 µM oligonucleotide) for 4 h. The oligonucleotide-containing medium was then replaced with normal growth medium, and growth was continued for 48 h to allow Ras turnover plus reduced Ras mRNA levels to result in reduced Ras protein levels (34).

RT-PCR and Sequencing-- Total RNA was isolated from monolayer cultures with TRIzol (Life Technologies, Inc.) according to the supplier's manual. RNA was treated with DNase I (amplification-grade; Life Technologies, Inc.) and RT-PCR was performed on a PerkinElmer Life Sciences DNA Thermal Cycler 480 using a Promega Access RT-PCR kit as follows and using the primers and conditions described previously (31). The amplification products were analyzed by ethidium bromide-agarose gel electrophoresis. The primer set used for RT-PCR of betaglycan mRNA yielded an expected amplification product of 592 bp, whereas primers for glyceraldehyde-3-phosphate dehydrogenase from CLONTECH gave a product of 452 bp.

Cell Culture and Growth Studies-- Derivation of the oncogenic Ki-ras and wild-type Ki-ras transfectants was as described (35). All cell lines were maintained in low glucose DMEM buffered with 25 mM Hepes (Atlanta Biologicals, Inc.) and containing 7% fetal bovine serum as described (32). Cell density was carefully controlled in these experiments. Within 1 day of growth to confluency, cells were plated at one-third confluent density and then used 2 days later. Serum-free transferrin/selenious acid-supplemented DMEM was used for the TGF-beta 1 growth experiments (33). TGF-beta 1-treated cells were less adherent, so both adherent and floating cells were analyzed for [3H[TdR incorporation after 3 h of labeling as described (33). Parallel wells that were not seeded with cells were washed to remove nonspecifically bound label, which was subtracted from all experimental values.

Transient Transfection of Betaglycan-- The c-Myc-tagged rat betaglycan expression plasmid pCMV-mycBGL was received from J. Massague (7) and subcloned into the retroviral vector pLXSN (CLONTECH). The recombinant retrovirus was used to infect mutant Ki-ras transfectant cells and control cells.

Immunoprecipitation of Tbeta RIII following [35S]Methionine Labeling-- Cells were incubated with 100 µCi/ml [35S]methionine in methionine-free DMEM for 6 h before lysates were prepared. 500 µg of cell lysates were incubated overnight at 4 °C with 2 µg of anti-Tbeta RIII antibody and 40 µl of protein G Plus-agarose (Santa Cruz Biotechnology), pelleted at 2500 rpm, and washed three times with lysis buffer. After the final wash, the pellet was mixed with 50 µl of SDS sample buffer and boiled in a water bath for 5 min. Aliquots were analyzed by SDS-PAGE, and Tbeta RIII was detected by Western blotting using anti-Tbeta RIII antibody and horseradish peroxidase-conjugated rabbit anti-goat IgG (Zymed Laboratories Inc.) and ECL.

Digestion with Endoglycosidase F-- Cell lysates were diluted 1:5 with detergent-free lysis buffer and then incubated for 36 h with chondroitinase ABC (2 units/ml), heparitinase (2 units/ml), and N-glycosidase F (5 units/ml) before SDS-PAGE and Western blot analysis.

Immunodetection-- Cells grown in complete medium were lysed in buffer containing 25 mM Tris (pH 7.4), 1% Triton X-100, 20 µg/ml leupeptin, 20 µg/ml aprotinin, 0.5 mM phenylmethylsulfonyl fluoride, 200 µM sodium orthovanadate, and 20 mM sodium fluoride. Depending on the experiment, 30-70 µg of cell lysate proteins were blotted onto polyvinylidene difluoride membranes after separation by SDS-PAGE. The blots were blocked in blocking buffer (Tris-buffered saline containing 0.05% Tween 20 and 4% nonfat dry milk) for 1 h at room temperature. Primary antibodies were used in Tris-buffered saline containing 0.05% Tween 20 and 1% dry milk at the indicated concentrations (anti-p21Cip1/Waf1, 1 µg/ml; anti-Tbeta RI, 1 µg/ml; anti-Tbeta RII, 1 µg/ml; and anti-Tbeta RIII (betaglycan), 1 µg/ml) and dilutions (1:1000 TGF-beta 1, 1:1000 PTEN, 1:1000 phospho-SMAD2 and total SMAD2, and 1:1000 phosphotyrosine) and then incubated for 2-3 h with primary antibody, and proteins were subsequently detected by ECL (Amersham Pharmacia Biotech). For p21Cip1 blots, cells were lysed in radioimmune precipitation assay buffer, and blocking was performed in 1% dry milk plus 4% bovine serum albumin. For SMAD2 blots, the first antibody was diluted in 5% bovine serum albumin, and the second in 2.5% dry milk. Affinity labeling of TGF-beta receptors with 125I-TGF-beta 1 was performed essentially as described (33).

Cell-surface Biotinylation and Immunoprecipitation of Tbeta RI and Tbeta RII-- Cell-surface proteins were biotinylated essentially as described by the vendor (Amersham Pharmacia Biotech). Briefly, exponentially growing cells were washed once with cold phosphate-buffered saline and once with 40 mM sodium bicarbonate (pH 8.6). Cells were then incubated for 30 min at 4 °C in 40 mM bicarbonate buffer containing 50 µl of biotin reagent/ml of buffer, 4 ng/ml TGF-beta 1, and 1 mg/ml bovine serum albumin (fatty acid-free). Following two washes with cold phosphate-buffered saline, cells were lysed in 25 mM Tris buffer containing 1% Triton X-100, 20 µg/ml leupeptin, 20 µg/ml aprotinin, 0.5 mM phenylmethylsulfonyl fluoride, 200 µM sodium orthovanadate, and 20 mM sodium fluoride. 300 µg of each cell lysate were incubated overnight at 4 °C with 200 µl of streptavidin coupled to agarose beads (Sigma). The beads were then washed extensively and resuspended in SDS-PAGE sample buffer. Cell-surface Tbeta RI and Tbeta RII were immunoprecipitated with anti-Tbeta RII antibody C-16 with or without Tbeta RII peptide C-16 (Santa Cruz Biotechnology) or with anti-Tbeta RI antibody R-20 (Santa Cruz Biotechnology)Biotechnology; antibodies were bound with horseradish peroxidase-streptavidin after washing and then detected with ECL.

Statistical Analysis-- Calculations measuring the difference between two means were performed by the t test.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Oncogenic Ki-ras Transfectants Gain Response to TGF-beta 1-- The Ki-rasG12V transfectant cloned sublines V, V1, and V2 were isolated following stable transfection of HD6-4 colon carcinoma cells with a mini-gene construct of the cellular Ki-ras4B gene mutated at codon 12 to valine. Three stable sublines (G, G2, and G3) were isolated following transfection with the wild-type mini-gene construct of cellular Ki-ras4B (35, 36). The Ki-rasG12V transfectant lines expressed oncogenic Ki-Ras protein, whereas the wild-type Ki-ras transfectant G lines expressed more wild-type Ki-Ras protein as shown by Western blotting with Ki-Ras-specific and pan-RasVal12-specific antibodies (35).

The parental line is not responsive to TGF-beta 1 (31-33), but unexpectedly became TGF-beta 1-responsive following expression of oncogenic Ki-Ras protein. Ki-rasG12V transfectant V cells exhibited a rapid increase in tyrosine phosphorylation of an unknown cellular protein of ~60 kDa after addition of TGF-beta 1, whereas no increase in tyrosine phosphorylation of this or any other protein was found in control cells treated with TGF-beta 1 (Fig. 1A). The 60-kDa protein showed increased tyrosine phosphorylation following 5 and 15 min of TGF-beta 1 treatment (Fig. 1A, arrow), whereas the abundance of phosphotyrosine in a 200-kDa protein remained constant, demonstrating equal loading. The chief mediators of TGF-beta signaling are the SMAD family of structurally related proteins. Upon TGF-beta receptor activation, Tbeta RI activates phosphorylation of SMAD2 and/or SMAD3, each of which can form an association with the common mediator SMAD4 and then translocate to the nucleus and mediate transcription (reviewed in Refs. 11 and 37). SMAD2 is activated by phosphorylation of serines 465 and 467 (38). 30 min of TGF-beta 1 treatment caused a striking increase in the activation of phosphorylation of SMAD2 in the oncogenic Ki-ras V transfectant, but no activation in control cells (Fig. 1B). A slight increase in the total amount of SMAD2 and SMAD3 in the Ki-ras V transfectant was also detected by Western blotting. Thus, expression of mutant Ki-Ras protein unexpectedly restored an initial step in a TGF-beta signaling pathway in these cells.



View larger version (31K):
[in this window]
[in a new window]
 
Fig. 1.   Ki-rasG12V transfectant cells respond to TGF-beta 1, but wild-type ras cells do not. A, parallel cultures of Ki-rasG12V transfectant V cells and parental wild-type ras cells (RasWT) were treated with 8 ng/ml TGF-beta 1 for 0, 5, 15, or 30 min, and cell lysates were prepared and analyzed by Western blotting with anti-phosphotyrosine (P-Tyr) antibody. The arrow marks a protein exhibiting an increase in phosphotyrosine content only in the Ki-rasG12V transfectant V cells. A 200-kDa protein exhibited similar phosphotyrosine content at all time points in both cell types. B, parallel cultures of Ki-rasG12V transfectant V cells and wild-type Ki-ras transfectant G cells were treated with 1 ng/ml TGF-beta 1 for 30 min before cell lysis and Western blotting with antibody directed to SMAD2 phosphorylated at serines 465 and 467 (P-Smad2) and with antibody to total SMAD2/SMAD3. The lower panel shows cellular proteins of 55-60 kDa after the Western blot was stained with Coomassie Blue to demonstrate equal loading and transfer. IB, immunoblotting.

Response to TGF-beta 1 by Oncogenic Ki-ras Transfectants Consistent with Tumor Progression-- The Ki-rasG12V transfectant lines were more tumorigenic in vivo and more invasive in vitro than the control cells (35, 36). Mutant Ki-Ras caused aberrant post-translational glycosylation of beta 1 integrin, loss of cellular adhesion to the extracellular matrix, blocked cell polarization, and decreased cell-cell adhesion properties through up-regulation of carcinoembryonic antigen and down-regulation of N-cadherin (35, 36). These decreases in attachment to the extracellular matrix and intercellular adhesion provide one basis for selection for Ki-ras mutations in colon cancers.

We had noted in past experiments that certain highly aggressive or metastatic colon cancer cells responded to TGF-beta 1 by increased cell growth (39-42) and wondered if the increased aggressiveness of the Ki-rasG12V transfectant cells in vivo reflected increased growth in response to autocrine or exogenous TGF-beta 1. TGF-beta 1 induced a statistically significant, dose-dependent increase in growth up to 2-fold in Ki-rasG12V transfectant V cells, whereas TGF-beta 1 induced no change in proliferation of parental cells grown in parallel (Fig. 2A, upper panel). The p value for mean growth ± 1 ng/ml TGF-beta 1 was <0.01, whereas the p values for growth ± 2 and 4 ng/ml TGF-beta 1 were both <0.001, all statistically significant differences. This growth response to TGF-beta 1 was generalized by assaying two additional Ki-rasG12V transfectant cell lines, V1 and V2, and three other control lines at the optimal TGF-beta 1 concentration (Fig. 2B, upper panel). TGF-beta 1 at 4 ng/ml increased [3H[TdR incorporation 1.5- to >2-fold in V1 and V2 cells, with statistically significant p values of <0.0005. In contrast, TGF-beta 1 had no effect on cycling of wild-type Ki-ras transfectant G2 and G3 cells or the parental line with endogenous wild-type Ki-ras (Fig. 2B).



View larger version (37K):
[in this window]
[in a new window]
 
Fig. 2.   TGF-beta 1 stimulates proliferation of Ki-rasG12V transfectant cells and down-regulates levels of the Cdk inhibitor p21 and the tumor suppressor PTEN. A: upper panel, HD6-4 colon carcinoma cells stably transfected with Ki-rasG12V transfectant V cells and parental cells expressing only wild-type ras (RasWT) were treated for 54 h with increasing concentrations of TGF-beta 1 in serum-free transferrin/selenious acid-supplemented DMEM and then incubated with [3H[TdR for 3 h before analysis to measure cell proliferation. Both attached cells and loosely adherent cells were collected for this assay. All data are the mean of two experiments, each performed in triplicate. The t test demonstrated that the proliferation of TGF-beta 1-treated V cells was statistically greater than that of TGF-beta 1-treated control cells, with p values of <0.01, 0.001, and 0.001 for TGF-beta 1 levels of 1, 2, or 4 ng/ml, respectively. Error bars are shown only if the S.E. is >5%. Lower panel, TGF-beta 1 decreases the abundance of p21 and PTEN in Ki-rasG12V transfectant V cells. rasG12V and wild-type ras cells were treated for 54 h with increasing concentrations of TGF-beta 1 of 0, 1, 2, 4, and 8 ng/ml, and then the abundance of p21Cip/Waf1 and PTEN in cell lysates was determined by Western blotting. The lower panel shows cellular proteins of ~44 kDa detected in this immunoblot by staining with Coomassie Blue to demonstrate equal loading. B: upper panel, TGF-beta 1 stimulates proliferation of two other Ki-rasG12V transfectants. Four other stable ras transfectants, two with mutant Ki-rasG12V (V1 and V2 cells) and two with wild-type Ki-ras (G2 and G3 cells), and the parental line were treated with 4 ng/ml TGF-beta 1 or left untreated, and [3H[TdR incorporation for each cell line was determined as described for A. All data are the mean of two experiments, each performed in triplicate. The t test demonstrated that the proliferation of TGF-beta 1-treated V1 and V2 cells was statistically greater than that of untreated V1 and V2 cells, with p values <0.0005 for each line. Lower panel, Western blots for the Cdk inhibitor p21 and the tumor suppressor PTEN and a double protein band of ~44 kDa detected by Coomassie Blue staining of the Western blot to demonstrate equal loading.

The mechanism of this unexpected proliferative response to TGF-beta 1 was explored by assaying two proteins associated with tumorigenicity: the Cdk inhibitor p21Cip1/Waf1 (43, 44) and the tumor suppressor phosphatase PTEN (45, 46). p21Cip1/Waf1 inhibits cell cycling by targeting most Cdk-cyclin complexes, binding to them and inhibiting their kinase activity. PTEN is a phospholipid phosphatase, deleted or mutated in a wide variety of tumors (46). Loss of PTEN activity would up-regulate the activity of the serine/threonine kinase Akt, which is known to play an important role in generating cell survival signals (47-49). Ki-rasG12V transfectant V cells and control cells were treated for 2 days with 0, 1, 2, 4, or 8 ng/ml TGF-beta 1, and then cell lysates were blotted for abundance of p21 and PTEN (Fig. 2A, lower panel). In control cells with wild-type Ki-ras, TGF-beta 1 caused no alteration in the levels of either protein. However, in duplicate experiments, TGF-beta 1 induced a dose-dependent decrease in the abundance of the Cdk inhibitor p21Cip1/Waf1, with the optimal growth-stimulating concentration of 4 ng/ml TGF-beta 1 reducing p21 levels to 16% of the control. PTEN levels were decreased 6-fold by 2, 4, or 8 ng/ml TGF-beta 1 only in the mutant Ki-Ras transfectant V cells. Coomassie Blue staining of the blot demonstrated equal loading (Fig. 2A, lower panel).

The generality of these responses was determined by assaying several more cell lines. Levels of p21Cip1/Waf1 and PTEN were examined in two other oncogenic Ki-ras transfectant lines (V1 and V2), two wild-type Ki-ras transfectant lines (G2 and G3), and the parental line with endogenous wild-type ras. Treatment with the optimal concentration of 4 ng/ml TGF-beta 1 decreased p21 levels in V1 and V2 cells expressing mutant Ki-Ras by 52 and 90%, respectively, whereas no decreases in p21 levels were observed in G1 and G3 lines with wild-type ras (Fig. 2B, lower panel). Treatment with 4 ng/ml TGF-beta 1 decreased PTEN levels in V1 and V2 cells expressing mutant Ki-Ras by 50 and 30%, respectively, in duplicate experiments. In contrast, no decreases were observed in PTEN levels in G2 and G3 cells expressing only wild-type Ki-ras. Thus, TGF-beta 1 acts like a mitogen in mutant Ki-ras-transformed colon carcinoma cells, possibly by decreasing the abundance of the Cdk inhibitor p21Cip1/Waf1. The loss of PTEN expression with TGF-beta 1 treatment may contribute to the aggressive growth of each Ki-rasG12V transfectant cell line in vivo, as cells can respond to TGF-beta 1 from autocrine or paracrine sources (35). These experiments demonstrate that oncogenic Ki-ras can confer a more aggressive, tumorigenic phenotype in colon cancer cells by altering their response to TGF-beta 1.

The Cdk inhibitor p21 is induced by TGF-beta 1 acting at the transcriptional level in several cell types, including (most if not all) epithelial cells (50, 51), but decreases in p21 abundance are seen when cells are treated with a mitogen. TGF-beta 1 has also been reported to rapidly down-regulate expression of PTEN at the transcriptional level in human keratinocyte HaCaT cells (45). Ongoing studies are exploring the mechanisms for these changes. In the following studies, we provide the mechanism for the gain of response to TGF-beta 1 by oncogenic ras.

Functional TGF-beta Receptors Induced in Ki-rasG12V Transfectants without Changes in Tbeta RI, Tbeta RII, or TGF-beta 1 Abundance or Mobility-- Functional Tbeta RI, Tbeta RII, and Tbeta RIII receptors had not been detected in parental cells expressing wild-type Ki-ras in earlier studies using cross-linking of 125I-TGF-beta 1 (33, 31). TGF-beta 1-binding proteins on the surface of viable cells were chemically cross-linked with 125I-TGF-beta 1 and then molecularly sized by SDS-PAGE and detected by autoradiography. Functional Tbeta RI and Tbeta RII and a polydisperse band of higher molecular mass TGF-beta 1-binding proteins of the size of Tbeta RIII were detected in each Ki-rasG12V transfectant line (V, V1, and V2). In contrast, the parental line HD6-4 expressing only endogenous wild-type Ki-ras (Fig. 3, left panel, WT lane) and the wild-type Ki-ras transfectant G cell line (right panel) exhibited no detectable TGF-beta 1 binding. Identical amounts of labeled TGF-beta 1 were detected on each lane in the autoradiograph, demonstrating equal loading. The parental cells displayed no binding of 125I-TGF-beta 1, although neither the Tbeta RII nor Tbeta RI receptor was mutated, and these cells exhibited cell-surface Tbeta RI and Tbeta RII proteins at levels equal to those seen in TGF-beta 1-responsive cells, indicating that receptor localization was not altered (31). Thus, functional Tbeta RI, Tbeta RII, and Tbeta RIII were detected in each of three Ki-rasG12V transfectant lines, but in neither control line.



View larger version (77K):
[in this window]
[in a new window]
 
Fig. 3.   Functional TGF-beta receptors found after stable transfection of Ki-rasG12V in each of three lines. Viable parental HD6-4 cells (wild-type (WT)), rasG12V cells (V, V1, and V2), and stable wild-type Ki-ras transfectant G cells were cross-linked with 125I-TGF-beta 1, and then cell lysates were analyzed by autoradiography following size fractionation by 5-8% gradient SDS-PAGE and electroblotting to polyvinylidene difluoride membrane. The positions of Tbeta RI, Tbeta RII, and the region where polydisperse Tbeta RIII migrates are indicated. Non-cross-linked 125I-TGF-beta 1 is seen at the bottom of the blot.

Possibly oncogenic Ki-Ras could increase the ability of TGF-beta receptors to bind 125I-TGF-beta 1 by altering the level of autocrine TGF-beta 1. However, no difference in the level of mature TGF-beta 1 was discerned between the Ki-rasG12V transfectant V cells and parental cells (Fig. 4). Thus, oncogenic Ki-Ras protein did not alter the abundance or electrophoretic mobility of autocrine TGF-beta 1. No differences in cellular abundance, cell surface levels, or electrophoretic mobility of Tbeta RI or Tbeta RII were detected in the two cell types, expressing either wild-type or mutant Ki-Ras (Fig. 5). Total Tbeta RI levels were assayed by Western blotting (Fig. 5A), and cell-surface Tbeta RI levels were assayed by immunoprecipitation following biotinylation (Fig. 5C). Total Tbeta RII levels were assayed by immunoprecipitation (Fig. 5B), and cell-surface Tbeta RII levels were assayed by immunoprecipitation following biotinylation (Fig. 5C). Each experiment was controlled by absorption of the antibody with specific peptides corresponding to either Tbeta RI or Tbeta RII. The biotinylation experiment demonstrated that equal amounts of the Tbeta RI and Tbeta RII proteins reached the cell surface of cells expressing either wild-type or mutant Ki-Ras. Thus, the increased binding of 125I-TGF-beta 1 in the oncogenic Ki-ras transfectant cells (Fig. 3) was not a result of increased transport of receptor proteins to the cell surface. These results, taken together, demonstrate that expression of oncogenic Ki-Ras protein did not alter the abundance, cell-surface expression, or electrophoretic mobility of either Tbeta RI or Tbeta RII, although these receptors regained the ability to bind exogenous 125I-TGF-beta 1 when oncogenic Ki-Ras protein was expressed.



View larger version (56K):
[in this window]
[in a new window]
 
Fig. 4.   Stable transfection of oncogenic Ki-ras does not alter abundance or migration of TGF-beta 1. Left panel, Western blot for TGF-beta 1 in parental wild-type ras cells (RasWT) and rasG12V transfectant V cells; right panel, Coomassie Blue-stained Western blot to demonstrate equal loading. IB, immunoblotting.



View larger version (31K):
[in this window]
[in a new window]
 
Fig. 5.   Stable transfection of oncogenic Ki-ras does not alter total abundance, cell-surface abundance, or electrophoretic mobility of Tbeta RI or Tbeta RII. A, shown are parallel Western blots for Tbeta RI in lysates from parental HD6-4 cells (RasWT) and rasG12V transfectant V cells. The + lanes were blotted in the presence of the immunizing receptor I peptide to demonstrate specificity of the blotting. B, Tbeta RII was detected by immunoprecipitation (IP) of lysates from parental wild-type ras cells and rasG12V V transfectant cells. A duplicate wild-type sample was immunoprecipitated in the presence of the receptor II peptide immunogen as a control, The arrowhead indicates Tbeta RII. C, proteins at the cell surface of parental wild-type ras cells and rasG12V transfectant V cells were biotinylated, and then Tbeta RI and Tbeta RII were immunoprecipitated and then detected by ECL. In the + lane, immunoprecipitation was performed in the presence of the immunizing receptor I or II peptide to demonstrate specificity of the immunoprecipitation. Arrowheads indicate Tbeta RI (RI) and Tbeta RII (RII). Similar levels of nonspecific bands in each blot demonstrate equal loading. IB, immunoblotting.

Restoration of Tbeta RIII function by itself might explain the ability of Tbeta RI and Tbeta RII to bind TGF-beta 1 since the parental cells exhibit incomplete post-translational modification of Tbeta RIII (31). Tbeta RIII functions by concentrating TGF-beta in the cell periphery and presenting it to Tbeta RII (8, 9, 52). Tbeta RII then forms a complex with Tbeta RI and phosphorylates Tbeta RI, transmitting the TGF-beta 1 signal (53). Therefore, expression of mutant Ki-Ras was closely correlated with gain of TGF-beta receptor function.

Increased Post-translational Modification of Endogenous Betaglycan/Tbeta RIII in Oncogenic Ki-rasG12V Transfectants-- The major form of Tbeta RIII found in HD6-4 colon carcinoma cells is betaglycan, whose core protein migrates at ~110 kDa (31). Very little post-translational modification of betaglycan occurs in parental cells with wild-type ras (31). In TGF-beta 1-responsive colon carcinoma cells, in contrast, betaglycan migrates as more modified forms at 120 and 140 kDa as well as a heterogeneous diffuse group of species above 200 kDa (31). Post-translational glycosylation of the integrin beta 1-chain was found to be aberrant in each of the oncogenic Ki-ras transfectants (35), suggesting that post-translational glycosylation of betaglycan might also be altered. Oncogenic forms of ras genes have been implicated in modulating various Golgi acetylglucosaminyltransferases in different cell types (54, 55). Western blotting for Tbeta RIII revealed new high molecular mass bands for each of the three Ki-rasG12V transfectants, but not for the wild-type Ki-ras G cells (data not shown), indicating greater post-translational modification of betaglycan. Thus, oncogenic Ki-Ras might up-regulate an acetylglucosaminyltransferase or a galactosyltransferase, which would modify betaglycan and restore its biological function.

The post-translational modifications of endogenous betaglycan were analyzed in Ki-rasG12V transfectant V cells by immunoprecipitation after prelabeling cellular proteins with [35S]methionine. Betaglycan forms were size-fractionated on gradient SDS-PAGE and detected by autoradiography. In control cells with wild-type ras, betaglycan/Tbeta RIII migrated as a core peptide of 110 kDa (Fig. 6A, left panel) and one higher molecular mass, but low abundant diffuse band (arrows). Thus, little post-translational modification occurred in control cells, as reported previously (31). In contrast, three higher molecular mass betaglycan species in addition to the core protein were detected in lysates from Ki-rasG12V transfectant cells (Fig. 6A, left panel, arrowheads). Therefore, at least some of the high molecular mass 125I-TGF-beta 1-binding proteins detected in each Ki-rasG12V transfectant line (Fig. 3) were post-translationally modified betaglycan/Tbeta RIII.



View larger version (60K):
[in this window]
[in a new window]
 
Fig. 6.   More abundant post-translational modification of endogenous Tbeta RIII in rasG12V cells. A: left panel, wild-type ras (RasWT) and rasG12V (P and V cells) were prelabeled with [35S]methionine, and then Tbeta RIII was immunoprecipitated, size-fractionated by SDS-PAGE, and autoradiographed. The upper region of the autoradiograph is shown, including the core peptide (arrow). There are three polydisperse bands of post-translationally modified Tbeta RIII in rasG12V transfectant cells (arrowheads on the right), but only one major band in the control wild-type ras cells (arrowhead on the left). Right panel, the lysates were treated with N-glycosidase F, heparitinase, and chondroitinase ABC to remove proteoglycan chains and glycosylations before immunoprecipitation of Tbeta RIII. Post-translational modifications of Tbeta RIII were lost, leaving only similar levels of core protein. B, semiquantitative RT-PCR demonstrated that there are similar levels of betaglycan mRNA in rasG12V transfectant V, V1, and V2 cells compared with wild-type ras transfectant G, G2, and G3 cells. In the three control lanes, no mRNA was added (first lane), or no reverse transcriptase was added to the mRNA preparations (second and third lanes). The positions of the betaglycan 592-bp PCR product and the 452-bp internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) product are indicated. Degly, deglycosylated.

We next questioned whether the post-translational modification of betaglycan induced by mutant Ki-Ras was similar to that seen in other TGF-beta 1-responsive cells. In such cells, the betaglycan core protein is heavily modified by glycosaminoglycan groups and by N-glycosylation (56). The betaglycan in V cells and in parental cells was chemically deglycosylated with N-glycosidase F, and proteoglycan groups were removed by digestion with heparitinase and chondroitinase ABC (Fig. 6A, right panel). These treatments have been shown to reduce betaglycan to its protein core (56). After treatment, equal amounts of betaglycan core protein were immunoprecipitated from prelabeled V cells and control cells, and the core proteins displayed equivalent electrophoretic migration rates (Fig. 6A, left and right panels). Thus, mutant Ki-Ras functioned at the level of post-translational modification of betaglycan, just as mutant Ki-Ras functioned in the same cells to modulate post-translational modification of beta 1 integrin (35).

These data indicated that betaglycan mRNA levels should be similar in mutant Ki-Ras and control cells. Similar amounts of betaglycan mRNA were detected in Ki-rasVal12 transfectant and control cells by semiquantitative RT-PCR (Fig. 6B), consistent with the equal levels of betaglycan core peptide exhibited in each cell line. These data suggest that mutant Ki-Ras functions to increase betaglycan modification, not to increase the abundance of the betaglycan core protein.

More Abundant Post-translational Modification of Transiently Transfected Betaglycan in Ki-rasG12V Transfectant Cells-- To confirm that betaglycan was highly modified following translation in Ki-rasG12V transfectant cells, betaglycan tagged with a c-Myc epitope was inserted into a retroviral vector. Both Ki-rasG12V transfectant V cells and control cells expressing wild-type Ki-ras were infected with this recombinant retrovirus. The predominant betaglycan species immunoprecipitated from control cells was the core peptide (Fig. 7). Therefore, very little post-translational modification of betaglycan occurred in cells with wild-type ras, consistent with the data on endogenous betaglycan shown in Fig. 6A. Moreover, highly modified, polydisperse betaglycan was synthesized in the Ki-rasG12V transfectant V cells (Fig. 7), again confirming the increased post-translational modification of endogenous betaglycan (Fig. 6A). Control experiments were carried out with the retroviral vector alone (data not shown) or without the c-Myc antibody in immunoprecipitations (- lanes). Note that equal amounts of IgG were found in each antibody lane, confirming the additional of equal amounts of antibody. Therefore, betaglycan/Tbeta RIII, whether transfected or endogenous, was highly modified following translation in the Ki-rasG12V transfectant cells, but not in control cells expressing only wild-type Ki-ras.



View larger version (35K):
[in this window]
[in a new window]
 
Fig. 7.   Exogenous betaglycan is highly modified in rasG12V transfectants. rasG12V (V clone) and parental wild-type ras (RasWT) cell lines were infected with either a recombinant retrovirus encoding a Myc-tagged betaglycan gene (LXSN-Myc-BG) or a recombinant retrovirus encoding only the c-Myc expression tag (LXSN-Myc). After 48 h of culture to allow expression and post-translational modification of betaglycan, the expressed betaglycan was immunoprecipitated (IP) by its c-Myc tag and analyzed by Western blotting with anti-Tbeta RIII antibody. The core betaglycan peptide was synthesized in both cell types (myc-BG core), but was highly modified only in rasG12V cells (myc-BG). Similar levels of IgG were detected in each immunoprecipitate as controls. Ab, antibody.

Antisense Oligonucleotides to Ki-Ras Decrease Post-translational Modification of Betaglycan and Block Down-regulation of p21 by TGF-beta 1-- The possibility was investigated that betaglycan modifications occurred as a result of adaptation of Ki-rasG12V transfectants to culture and were not directly related to expression of mutant Ki-Ras protein. Therefore, the expression of mutant Ki-rasG12V in V2 cells was decreased by treatment with phosphorothiolated antisense oligonucleotides targeted to Ki-Ras. This treatment almost completely eliminated the expression of the mutant Ki-Ras protein in V2 cells compared with cells treated in parallel with random sequence oligonucleotides, as shown by Western blotting with a pan-RasVal12-specific antibody (Fig. 8A, left panel). Phosphorothiolated antisense oligonucleotides directed to mutant Ki-Ras block the abnormal glycosylation of the integrin beta 1-chain in V2 cells (35), so we expected that blocking mutant Ki-Ras would alter betaglycan modification. The sharp decrease in mutant Ki-Ras protein caused a marked decrease in the abundance of the most highly modified betaglycan species in the Ki-ras antisense oligonucleotide-treated cells (Fig. 8A, right panel) compared with cells treated with random sequence oligonucleotides. The decrease in betaglycan modification was dependent on the concentration of phosphorothiolated antisense oligonucleotides, with the greatest effect seen at 200 nM. Each of the lysates exhibited similar amounts of core protein, demonstrating equal loading. Therefore, the increased post-translational modification of betaglycan/Tbeta RIII found in each of the oncogenic ras transfectant lines was due to expression of the mutant Ki-ras gene.



View larger version (58K):
[in this window]
[in a new window]
 
Fig. 8.   Antisense oligonucleotides directed to Ki-Ras greatly decreases expression of mutant Ki-RasVal12 protein, decrease Tbeta RIII post-translational modification in Ki-rasG12V cells, and block induction of p21 by TGF-beta 1. A: left panel, rasG12V transfectant V2 cells were treated for 4 h with phosphorothiolated antisense oligonucleotides or phosphorothiolated random sequence oligonucleotides or left untreated (control lane) and then washed and cultured in oligonucleotide-free medium for 48 h to allow Ras turnover plus reduced Ras mRNA levels to result in reduced Ki-Ras protein. Western blotting was performed with pan-RasVal12 monoclonal antibody, which detects only the forms of the oncogenic Ras protein mutated at codon 12 to valine. Right panel, Tbeta RIII was immunoprecipitated (IP) after treatment with antisense or random sequence oligonucleotides. During the last overnight incubation in A, cells were prelabeled with [35S]methionine, and then Tbeta RIII was immunoprecipitated, size-fractionated by SDS-PAGE, and autoradiographed. The upper region of the autoradiograph is shown, and post-translationally modified Tbeta RIII (RIII) is indicated as well as the faster migrating core peptide that was present at similar levels in each immunoprecipitate. B, rasG12V transfectant V2 cells were treated as described for A with 200 nM antisense oligonucleotides directed to Ki-Ras or 200 nM random sequence oligonucleotides. After culture for 6 h in oligonucleotide-free complete DMEM, cells were treated with 4 ng/ml TGF-beta 1 in serum-free transferrin/selenious acid-supplemented DMEM for 44 h or left untreated. The abundance of the Cdk inhibitor p21 was then analyzed by Western blotting. The abundance of a nonspecific protein on the Western blot is shown (Protein level) to demonstrate equal loading and transfer. IB, immunoblotting; RasWT, wild-type ras cells.

We next tested whether blocking expression of the mutant Ki-ras gene would also block response to TGF-beta 1. V2 cells were treated with equal concentrations (200 nM) of either phosphorothiolated antisense oligonucleotides to Ki-Ras or phosphorothiolated random sequence oligonucleotides as described above and then treated for 2 days with 4 ng/ml TGF-beta 1 or left untreated. TGF-beta 1 down-regulated the abundance of the Cdk inhibitor p21Cip1/Waf1 in V2 cells pretreated with random sequence oligonucleotides in duplicate experiments analyzed by Western blotting (Fig. 8B). However, the TGF-beta 1 response was blocked in V2 cells treated with antisense oligonucleotides to down-regulate mutant Ki-Ras, and the abundance of p21Cip1/Waf1 was unchanged (Fig. 8B). The abundance of a cellular protein slightly larger than p21Cip1/Waf1 is also shown to demonstrate equal loading and blotting. These experiments demonstrate that the increased post-translational modification of betaglycan/Tbeta RIII observed in each Ki-rasG12V transfectant line and the response of the Ki-rasG12V transfectant cells to TGF-beta 1 were caused by expression of the mutant Ki-ras gene.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Tbeta RIII or betaglycan is the most abundant TGF-beta -binding protein in a number of cell types. Betaglycan has a small cytoplasmic domain with no consensus signaling motif (7, 9), so it is not believed to directly transduce TGF-beta signaling. However, in the absence of Tbeta RIII, only a small fraction of Tbeta RII in myoblasts binds TGF-beta 1 with high affinity, whereas expression of Tbeta RIII in these cells converts the majority of Tbeta RII molecules to high affinity TGF-beta 1 receptors (52). Thus, the major role of Tbeta RIII is believed to be its ability to concentrate TGF-beta 1 and present it to the signaling receptors, Tbeta RII and Tbeta RI. The role of Tbeta RIII is not limited to binding exogenous TGF-beta 1. Stable transfection of Tbeta RIII in MCF-7 breast cancer cells restores autocrine TGF-beta 1 signaling as well (57).

In this study, we have shown that both functional, post-translationally modified Tbeta RIII and the biological response to TGF-beta 1 were restored by stable expression of oncogenic Ki-rasVal12 in HD6-4 colon carcinoma cells. Both responses were blocked by phosphorylated antisense oligonucleotides, which markedly reduced the abundance of mutant Ki-Ras protein, proving that the changes in TGF-beta receptors and response were caused by the mutant Ki-Ras protein. The oncogenic Ki-rasVal12 cell lines had been shown in earlier studies to have altered post-translational glycosylation of beta 1 integrin (35), so the post-translational modification of Tbeta RIII shown in the this study may also be glycosylation. TGF-beta 1 mediates glycosylation of beta 1 integrin in colon carcinoma cells by activating Ras proteins (58). The TGF-beta 1/Ras pathway functions to convert a partially glycosylated beta 1 integrin precursor into the mature, fully glycosylated form and is blocked by dominant-negative N17Ras (58). In like fashion, constitutive activation of Ki-Ras in stable oncogenic Ki-ras transfectants may up-regulate glycosyltransferases that modify Tbeta RIII. beta 1-6-N-Acetylglucosaminyltransferase V is increased severalfold in activity in rodent fibroblast lines transfected with the oncogenic T24 Ha-ras gene (54). In addition, NIH3T3 cells expressing the N-ras proto-oncogene exhibit 5-7-fold increases in the activities of beta 1-galactosyltransferase and beta 3-N-acetylglucosaminyltransferase, both of which synthesize polylactosaminoglycan chains (55). What is the biological significance of these observations? ras genes are mutated in about half of all colon cancers. The colon goblet cell lineage comprises 20% of the cells in the colonic crypt, so some of the ras mutations that occur in the development of colon cancer must take place in this lineage.

The parental HD6-4 cell line used in this study was shown earlier to respond to very high levels of TGF-beta 1 (100 ng/ml), 20-100 times more than used in this study, by induction of p21Cip1/Waf1 (31). Lower concentrations of 1-5 ng/ml TGF-beta 1, which initiated responses in other colon carcinoma cells and in the mutant Ki-Ras transfectants in this study, were ineffective on the parental HD6-4 cells (31). Very high TGF-beta 1 levels of 100 ng/ml could bypass the need for a functional Tbeta RIII to bind and concentrate TGF-beta 1 and to present it to the signaling receptors, leading us to hypothesize that, under these conditions, TGF-beta 1 bound directly to Tbeta RII. Supporting this hypothesis, expression of inducible dominant-negative Tbeta RII blocked signaling caused by very high TGF-beta 1 levels. Thus, signaling did occur through the Tbeta RII-mediated pathway. HD6-4 cells also responded to autocrine TGF-beta 1 by beta 1 integrin maturation, and this TGF-beta response to autocrine TGF-beta 1 was also blocked by inducible dominant-negative Tbeta RII (31). Therefore, before transfection with mutant Ki-ras, HD6-4 cells had intact TGF-beta signaling pathways. These intact pathways mediated induction of p21Cip1/Waf1 in response to TGF-beta 1 and maturation of beta 1 integrin in response to autocrine TGF-beta 1.

These results demonstrate that cells expressing mutant Ki-Ras became much more sensitive to added TGF-beta 1, and their response to TGF-beta 1 was altered. TGF-beta 1 was no longer capable of up-regulating levels of p21Cip1/Waf1 in mutant Ki-Ras cells as it did in the parental HD6-4 cell line (31) and, in fact, displayed the opposite response to TGF-beta 1, decreasing levels of p21Cip1/Waf1. It is not yet known whether the TGF-beta 1 effects on p21Cip1/Waf1 are mediated at the transcriptional or post-translational level. TGF-beta 1 is mitogenic in osteoblasts; and in these cells, TGF-beta 1 stimulated degradation of the Cdk inhibitors p57, p27, and p21 by the proteasome (59). Thus, TGF-beta 1 may induce rapid turnover of p21Cip1/Waf1 in oncogenic Ki-ras transfectants and, in so doing, increase their growth rate. In fact, Ki-ras transfectants grow much more quickly than control cells in athymic mice (35).

What is the basis for this switch in response to TGF-beta 1? The general picture has emerged that TGF-beta 1 has a dual role in carcinoma development: TGF-beta 1 inhibits the proliferation of normal cells (60, 61) and benign tumor cells (62), but enhances malignancy at later stages of tumorigenesis in cells that retain some response to TGF-beta (40, 63-66). Supporting this model are studies showing that TGF-beta 1 inhibits benign skin tumor formation, but enhances progression of skin tumors to invasive spindle carcinomas in carcinogen-treated transgenic mice with keratinocyte-targeted expression of TGF-beta 1 (67). The tumor-promoting effects of TGF-beta 1 are more evident when tumor cells are highly aggressive. The metastatic potential of mammary adenocarcinoma cells is increased by in vitro treatment with TGF-beta 1 before injection into syngeneic rats (68). Highly aggressive and metastatic U9 colon cancer cells use autocrine TGF-beta 1 to mediate their growth and invasion (40). Decreasing TGF-beta 1 protein levels in the metastatic U9 colon cancer cell line by antisense methodology decreases both U9 cell metastasis to the liver and subcutaneous tumor formation in a nude mouse system, and the tumors that do arise regain TGF-beta 1 expression (69). Also, levels of TGF-beta 1 protein within colon cancers and in serum are enhanced in patients whose disease progresses (70-73). Many other types of carcinomas, including pancreatic cancer, gastric cancer, endometrial cancer, breast cancer, gliomas, and osteosarcomas, also respond to TGF-beta 1 with disease progression (2).

The mechanism of this switch in response to TGF-beta 1 is unknown, but may include alterations in Ras. ras genes are mutated in ~30% of all cancers and about half of all colon cancers. In some cases, residual TGF-beta signaling pathways may remain functional after some TGF-beta signaling pathways are blocked by mutations in Tbeta RII or SMAD proteins (74-76). Such residual pathways may mediate epithelial-to-mesenchymal transdifferentiation (77). In ras-transformed cells, the TGF-beta 1 signaling cascade, which leads to growth inhibition, is blocked by MAPK phosphorylation of signal-transducing SMAD proteins (28). However, the ras-transformed cells retain TGF-beta response, demonstrating that these signals are relayed either by residual SMAD activity or by a SMAD-independent mechanism. In ras-transformed IEC cells, TGF-beta 1 growth resistance is lost, but the cells retain some TGF-beta signaling systems, as the cells remain responsive to TGF-beta 1 stimulation of fibronectin synthesis (78). Likewise, in ras-transformed mammary epithelial cells, TGF-beta 1 growth inhibition is lost, but is replaced by the capacity to undergo epithelial-to-mesenchymal transdifferentiation with increased cell invasiveness (29).

Autocrine TGF-beta 1 (Fig. 4) may mediate an epithelial-to-mesenchymal transdifferentiation in the ras-transformed HD6-4 colon carcinoma cells used in this study. ras transformation of colon carcinoma cells disrupts their basolateral polarity and decreases their lateral adherence by down-regulation of N-cadherin (36). The cells become rounded and less differentiated, are less adherent to laminin and collagen I because of blocked maturation of integrin beta 1, form multicellular aggregates, and grow much more rapidly in athymic mice (35). TGF-beta initiates several parallel signaling pathways with cellular responses determined by the set of transcription factors that are activated by separate and interacting TGF-beta pathways (79). After SMAD signaling is inhibited by mutant Ki-Ras, the TGF-beta 1 pathways left functioning may interact with pathways activated by mutant Ki-Ras to increase tumorigenicity. Such oncogenic ras-activated pathways include the post-translational modification of Tbeta RIII described in this study, the post-translational modification of beta 1 integrin (35), increases in growth rate through constitutive activation of MAPKs (35), and decreases in intercellular adhesion through up-regulation of carcinoembryonic antigen (36).


    FOOTNOTES

* This work was supported by National Cancer Institute Grant RO1 CA75708 from the National Institutes of Health (to E. F.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Pathology, Rm. 2305, Weiskotten Hall, Upstate Medical University, State University of New York, 750 East Adams St., Syracuse, NY 13210. Tel.: 315-464-7148; Fax: 315-464-8419; E-mail: friedmae@mail.upstate.edu.

Published, JBC Papers in Press, October 11, 2000, DOI 10.1074/jbc.M004553200


    ABBREVIATIONS

The abbreviations used are: TGF-beta , transforming growth factor-beta ; Tbeta R, transforming growth factor-beta receptor; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; TdR, thymidine; bp, base pair(s); DMEM, Dulbecco's modified Eagle's medium; RT-PCR, reverse transcription-polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Kingsley, D. (1994) Genes Dev. 8, 133-146[CrossRef][Medline] [Order article via Infotrieve]
2. Gold, L. (1999) Crit. Rev. Oncog. 10, 303-360[Medline] [Order article via Infotrieve]
3. Cui, W., and Akhurst, R. (1996) in Growth Factors and Cytokines in Health and Disease (Bondy, C. , and LeRoith, D., eds) , JAI Press, Greenwich, CT
4. Lin, H., Wang, X.-F., Ng-Eaton, E., Weinberg, R., and Lodish, H. (1992) Cell 68, 775-785[Medline] [Order article via Infotrieve]
5. Franzen, P., ten Dijke, P., Ichijo, H., Yamashita, H., Schultz, P., Heldin, D., and Miyazono, K. (1993) Cell 75, 681-692[Medline] [Order article via Infotrieve]
6. Wrana, J., Attisano, L., Wieser, R., Ventura, F., and Massague, J. (1994) Nature 370, 341-347[CrossRef][Medline] [Order article via Infotrieve]
7. Lopez-Casillas, F., Cheifetz, S., Doody, J., Andres, J., Lane, W., and Massague, J. (1991) Cell 67, 785-795[Medline] [Order article via Infotrieve]
8. Lastres, P., Letamendia, A., Zhang, H., Rius, C., Almendro, N., Raab, U., Lopez, L., Langa, C., Fabra, A., Letarte, M., and Bernabeu, C. (1996) J. Cell Biol. 133, 1109-1121[Abstract]
9. Wang, X.-F., Lin, H., Ng-Eaton, E., Downward, J., and Lodish, H. (1991) Cell 67, 797-805[Medline] [Order article via Infotrieve]
10. Ewton, D., Spizz, G., Olson, E., and Florini, J. (1988) J. Biol. Chem. 263, 4029-4032[Abstract/Free Full Text]
11. Derynck, R., Zhang, Y., and Feng, X.-H. (1998) Cell 95, 737-740[Medline] [Order article via Infotrieve]
12. Chen, X., Weisberg, E., Fridmacher, V., Watanabe, M., Naco, G., and Whitman, M. (1997) Nature 389, 85-89[CrossRef][Medline] [Order article via Infotrieve]
13. Liu, F., Pouponnot, C., and Massague, J. (1997) Genes Dev. 11, 3157-3167[Abstract/Free Full Text]
14. Zhang, Y., Feng, X.-H., and Derynck, R. (1998) Nature 394, 909-913[CrossRef][Medline] [Order article via Infotrieve]
15. Tsukazaki, T., Chiang, T., Davison, A., Attisano, L., and Wrana, J. (1998) Cell 95, 779-791[Medline] [Order article via Infotrieve]
16. Mulder, K., and Morris, S. (1992) J. Biol. Chem. 267, 5029-5031[Abstract/Free Full Text]
17. Yan, Z., Winawer, S., and Friedman, E. (1994) J. Biol. Chem. 269, 13231-13237[Abstract/Free Full Text]
18. Hartsough, M., Frey, R., Zipfel, P., Buard, A., Cook, S., McCormick, F., and Mulder, K. (1996) J. Biol. Chem. 271, 22368-22375[Abstract/Free Full Text]
19. Yamaguchi, K., Shirakabe, K., Shibuya, H., Irie, K., Oishi, I., Ueno, N., Taniguichi, T., Nishida, E., and Matsumoto, K. (1995) Science 270, 2008-2011[Abstract]
20. Shibuya, H., Yamaguchi, K., Shirakabe, K., Tonegawa, A., Gotoh, Y., Ueno, N., Irie, K., Nishida, E., and Matsumoto, K. (1996) Science 272, 1179-1182[Abstract]
21. Ventura, F., Liu, F., Doody, J., and Massague, J. (1996) J. Biol. Chem. 271, 13931-13934[Abstract/Free Full Text]
22. Wang, T., Danielson, P., Li, B.-Y., Shah, P., Kim, S., and Donahoe, P. (1996) Science 271, 1120-1122[Abstract]
23. Wang, T., Donahoe, P., and Zervos, A. (1994) Science 265, 674-676[Medline] [Order article via Infotrieve]
24. Sipes, N., Lyons, R., and Moses, H. (1990) Mol. Carcinog. 3, 12-19[Medline] [Order article via Infotrieve]
25. Houck, K., Michalopoulos, G., and Strom, S. (1989) Oncogene 4, 19-25[Medline] [Order article via Infotrieve]
26. Filmus, J., Zhao, J., and Buick, R. (1992) Oncogene 7, 521-526[Medline] [Order article via Infotrieve]
27. Longstreet, M., Miller, B., and Howe, P. (1992) Oncogene 7, 1549-1556[Medline] [Order article via Infotrieve]
28. Kretzschmar, M., Doody, J., Timokhina, I., and Massague, J. (1999) Genes Dev. 13, 804-816[Abstract/Free Full Text]
29. Oft, M., Peli, J., Rudaz, C., Schwarz, H., Berg, H., and Reichman, E. (1996) Genes Dev. 10, 2462-2477[Abstract]
30. Akhurst, R., and Balmain, A. (1999) J. Pathol. 187, 82-90[CrossRef][Medline] [Order article via Infotrieve]
31. Deng, X., Bellis, S., Yan, Z., and Friedman, E. (1999) Cell Growth Differ. 10, 11-18[Abstract/Free Full Text]
32. Hafez, M., Infante, D., Winawer, S., Friedman, E., Yan, Z., Hsu, S., Winawer, S., and Friedman, E. (1990) Cell Growth Differ. 1, 617-626[Abstract]
33. Yan, Z., Hsu, S., Winawer, S., and Friedman, E. (1992) Oncogene 7, 801-805[Medline] [Order article via Infotrieve]
34. Chen, G., Oh, S., Monia, B., and Stacey, D. (1996) J. Biol. Chem. 271, 28259-28265[Abstract/Free Full Text]
35. Yan, Z., Chen, M., Perucho, M., and Friedman, E. (1997) J. Biol. Chem. 272, 30928-30937[Abstract/Free Full Text]
36. Yan, Z., Deng, X., Chen, M., Xu, Y., Abram, M., Sloane, B., and Friedman, E. (1997) J. Biol. Chem. 272, 27902-27907[Abstract/Free Full Text]
37. Heldin, C., Miyazono, K., and ten Dijke, P. (1997) Nature 390, 465-471[CrossRef][Medline] [Order article via Infotrieve]
38. Abdollah, S., Macias-Silva, M., Tsukasaki, T., Hayashi, H., Attisano, L., and Wrana, J. (1997) J. Biol. Chem. 272, 27678-27685[Abstract/Free Full Text]
39. Schroy, P., Rifkin, J., Coffey, R., Winawer, S., and Friedman, E. (1990) Cancer Res. 50, 261-265[Abstract]
40. Hsu, S., Huang, F., Hafez, M., Winawer, S., and Friedman, E. (1994) Cell Growth Differ. 5, 267-275[Abstract]
41. Huang, F., Newman, E., Kerbel, R., and Friedman, E. (1995) Cell Growth Differ. 6, 1635-1642[Abstract]
42. Kansra, S., Ewton, D., Wang, J., and Friedman, E. (2000) Int. J. Cancer 87, 373-378[CrossRef][Medline] [Order article via Infotrieve]
43. El-Deiry, W., Tokino, T., Velculescu, V., Levy, D., Parsons, R., Trent, J., Lin, D., Mercer, W., Kinzler, K., and Vogelstein, B. (1993) Cell 75, 817-825[Medline] [Order article via Infotrieve]
44. Harper, J., Adami, G., Wei, N., Keyomarsi, K., and Elledge, S. (1993) Cell 75, 805-816[Medline] [Order article via Infotrieve]
45. Li, D., and Sun, H. (1997) Cancer Res. 57, 2124-2129[Abstract]
46. Maehama, T., and Dixon, J. (1999) Trends Cell Biol. 9, 125-128[CrossRef][Medline] [Order article via Infotrieve]
47. Khwaja, A. (1999) Nature 401, 33-34[CrossRef][Medline] [Order article via Infotrieve]
48. King, W., Mattaliano, M., Chan, T., Tsichlis, P., and Brugge, J. (1997) Mol. Cell. Biol. 17, 4406-4418[Abstract]
49. Downward, J. (1998) Curr. Opin. Cell Biol. 10, 262-267[CrossRef][Medline] [Order article via Infotrieve]
50. Datto, M., Li, Y., Panus, J., Howe, D., Xiong, Y., and Wang, X. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5545-5549[Abstract]
51. Li, C.-Y., Saurdet, L., and Little, J. (1995) J. Biol. Chem. 270, 4971-4974[Abstract/Free Full Text]
52. Lopez-Casillas, F., Wrana, J., and Massague, J. (1993) Cell 73, 1435-1444[Medline] [Order article via Infotrieve]
53. Massague, J. (1996) Cell 85, 947-950[Medline] [Order article via Infotrieve]
54. Dennis, J., Laferte, S., Waghorne, C., Breitman, M., and Kerbel, R. (1987) Science 236, 582-585[Medline] [Order article via Infotrieve]
55. Easton, E., Bolscher, J., and van den Eijnden, D. (1991) J. Biol. Chem. 266, 21674-21680[Abstract/Free Full Text]
56. Cheifetz, S., Andres, J., and Massague, J. (1988) J. Biol. Chem. 263, 16984-16991[Abstract/Free Full Text]
57. Chen, C., Wang, X.-F., and Sun, L. (1997) J. Biol. Chem. 272, 12862-12867[Abstract/Free Full Text]
58. Bellis, S., Newman, E., and Friedman, E. (1999) J. Cell. Physiol. 181, 33-44[CrossRef][Medline] [Order article via Infotrieve]
59. Urano, T., Yashiroda, H., Muraoka, M., Tanaka, K., Hosoi, T., Inoue, S., Ouchi, Y., Tanaka, K., and Toyoshima, H. (1999) J. Biol. Chem. 274, 12197-12200[Abstract/Free Full Text]
60. Alexandrow, M., and Moses, H. (1995) Cancer Res. 55, 1452-1457[Medline] [Order article via Infotrieve]
61. Roberts, A. B. (1998) Miner. Electrolyte Metab. 24, 111-119[CrossRef][Medline] [Order article via Infotrieve]
62. Manning, A., Williams, A., Game, S., and Paraskeva, C. (1991) Oncogene 6, 1471-1476[Medline] [Order article via Infotrieve]
63. Barrack, E. (1997) Prostate 31, 61-70[CrossRef][Medline] [Order article via Infotrieve]
64. Factor, V., Cao, C.-Y., Santoni-Rugiu, E., Woitach, J., Jensen, M., and Thorgeison, S. (1997) Cancer Res. 57, 2089-2095[Abstract]
65. Farina, A., Coppa, A., Tiberio, A., Tacconelli, A., Turco, A., Colletta, G., Gulino, A., and Mackay, A. (1998) Int. J. Cancer 75, 721-730[CrossRef][Medline] [Order article via Infotrieve]
66. Arteaga, C., Carty-Dugger, T., Moses, H., Hurd, S., and Pietenpol, J. (1993) Cell Growth Differ. 4, 193-201[Abstract]
67. Cui, W., Fowlis, D., Bryson, S., Duffie, E., Ireland, H., Balmain, A., and Akhurst, R. (1996) Cell 86, 531-542[Medline] [Order article via Infotrieve]
68. Welch, D., Fabra, A., and Nakajima, M. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7678-7682[Abstract]
69. Huang, F., Hsu, S., Yan, Z., Winawer, S., and Friedman, E. (1994) Oncogene 9, 3701-3706[Medline] [Order article via Infotrieve]
70. Friedman, E., Gold, L., Klimstra, D., Zeng, Z., Winawer, S., and Cohen, A. (1995) Cancer Epidemiol. Biomark. Prev. 4, 549-554[Abstract]
71. Tsushima, H., Kawata, S., Tamura, S., Ito, N., Shirai, Y., Kiso, S., Imai, Y., Shimomukai, H., Normura, Y., Matsuda, Y., and Matsuzama, Y. (1996) Gastroenterology 110, 375-382[Medline] [Order article via Infotrieve]
72. Robson, H., Anderson, E., James, R., and Schofield, P. (1996) Br. J. Cancer 74, 753-758[Medline] [Order article via Infotrieve]
73. Shim, K., Kim, K., Han, W., and Park, E. (1999) Cancer 85, 554-561[CrossRef][Medline] [Order article via Infotrieve]
74. Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R., Zborowska, E., Kinzler, K., Vogelstein, B., Brattain, M., and Willson, J. (1995) Science 268, 1336-1338[Medline] [Order article via Infotrieve]
75. Hahn, S., Schutte, M., Hoque, A. T. M. S., Moskaluk, C., da Costa, L., Rozenblum, E., Weinstein, C., Fischer, A., Yeo, C., Hruban, R. H., and Kern, S. (1996) Science 271, 350-353[Abstract]
76. Riggins, G., Kinzler, K., Vogelstein, B., and Thagalingam, S. (1997) Cancer Res. 57, 2578-2580[Abstract]
77. Miettinen, P., Ebner, R., Lopez, A., and Derynck, R. (1994) J. Cell Biol. 127, 2021-2036[Abstract]
78. Zhao, J., and Buick, R. (1995) Cancer Res. 55, 6181-6188[Abstract]
79. Zhang, Y., and Derynck, R. (1999) Trends Cell Biol. 9, 274-279[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.